• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-16

  The reference study identifies CD44 as a functional metabolic dependency in IDH-mutant leukemia, linking pentose phosphate pathway activity and NADPH production to sustained R-2HG synthesis. Its isogenic CRISPR design supports a mechanistic rationale for combining mutant-IDH inhibition with CD44 blockade in acute myeloid leukemia research, while also highlighting important limitations for clinical translation.

• Acetylspiramycin: Translating Ribosome Biology

  2026-09-16

  Acetylspiramycin, or Spiramycin B, is a mechanistically defined macrolide tool for connecting 50S ribosomal inhibition with susceptibility testing, resistance analysis, and host-response research. This translational perspective also shows how a refractory ocular infection case can sharpen—not overextend—interpretation of antimicrobial evidence.

• Dimetridazole Restores Cefotaxime Activity in MDR E. coli

  2026-09-15

  A 2025 Scientific Reports study shows that Dimetridazole can potentiate cefotaxime against multidrug-resistant E. coli through coordinated disruption of membrane integrity, permeability, and fatty acid biosynthesis. The work combines checkerboard synergy testing, membrane imaging, lipid analysis, gene-expression measurements, and a Galleria mellonella infection model to connect antibacterial activity with a plausible membrane-centered mechanism.

• EdU Imaging Kits (HF594): Practical Guide

  2026-09-15

  EdU Imaging Kits (HF594) provide a practical endpoint assay for measuring S-phase DNA synthesis in cultured cells by fluorescent click chemistry. They are suited to fluorescence microscopy and flow cytometry, but not to live-cell longitudinal tracking or workflows that require copper-free detection or completely unmodified native DNA.

• Psoralen Cholestasis and ERK1/2 Activation

  2026-09-14

  A 2024 Chemical Research in Toxicology study linked psoralen- and isopsoralen-induced cholestatic liver injury in zebrafish larvae to estrogen-like signaling, altered bile-acid regulation, and ERK1/2 activation. Its combination of functional liver phenotyping, gene-expression analysis, and pharmacological rescue positions ERK1/2 as a mechanistically testable target in phytoestrogen-associated cholestasis.

• Bestatin Dissects Jasmonate Signaling in Arabidopsis

  2026-09-14

  The reference study established bestatin as a chemical-genetic probe that activates jasmonate responses through a COI1-dependent mechanism while not requiring jasmonate biosynthesis in a strictly direct manner. By combining transcript profiling, developmental assays, and screening of bestatin-resistant mutants, the authors identified genetic classes and candidate loci that broaden experimental access to jasmonate signaling.

• Hexamethonium Bromide: Mapping Autonomic Control

  2026-09-13

  Hexamethonium Bromide enables mechanistic analysis of ganglionic control in cardiovascular and neuronal signaling experiments. This article explains how to use blockade results as causal evidence rather than treating them as a standalone blood-pressure endpoint.

• Mupirocin and Novobiocin in Canine Staphylococci

  2026-09-12

  The reference study compared mupirocin and novobiocin susceptibility in meticillin-susceptible and meticillin-resistant staphylococci recovered from healthy dogs and dogs with superficial pyoderma. Its paired sampling design shows that resistance phenotype and clinical context both influence interpretation of antibacterial testing in vitro, while also highlighting the differing reliability of topical and oral options.

• MLN2238: Proteasome β5 Subunit Inhibitor

  2026-09-11

  MLN2238 is a reversible proteasome β5 subunit inhibitor with nanomolar activity against the chymotrypsin-like site of the 20S proteasome. Its reported β5 selectivity, proteotoxic-stress signaling, and preclinical activity make it useful for multiple myeloma research, lymphoma research, apoptosis studies, and drug-resistance models.

• Ginsenoside Rg1: Neuroimmune Assay Workflows

  2026-09-11

  Ginsenoside Rg1 supports a mechanism-focused workflow that connects behavior, cytokines, synaptic physiology, gut-barrier integrity, and regulatory T-cell biology. Its water-insoluble, DMSO-compatible profile also makes formulation controls and vehicle matching central to reproducible neuroprotection research.

• Plant Cell Lysis Buffer for WB and IP Workflow

  2026-09-10

  Build a cold, native-state extraction workflow for plant tissues, protoplasts, and compatible mammalian samples with one inhibitor-containing formulation. The protocol connects reliable Western blotting, immunoprecipitation, and co-complex analysis to the MAPK10–KRT16 research framework while separating published evidence from practical optimization.

• Sodium Salicylate Workflows for NF-κB Research

  2026-09-10

  Build reproducible NF-κB, inflammation, and oxidative-stress assays with a highly soluble small-molecule comparator. This workflow also shows how sodium salicylate can complement, but not substitute for, sequential stromal-remodeling nanomedicine studies in pancreatic cancer.

• Dimethyloxalylglycine (DMOG) Protocol Guide

  2026-09-09

  Dimethyloxalylglycine (DMOG) provides a practical chemical approach for hypoxia-inducible factor stabilization under defined in-vitro conditions, supporting studies of oxygen sensing, hypoxia signaling, and inflammation. It is intended for scientific research only and should not be used for diagnostic, therapeutic, or medical applications.

• Losartan Experimental Workflows for AT1 Biology

  2026-09-09

  Losartan is a practical angiotensin II receptor antagonist for connecting AT1 signaling with vascular smooth muscle behavior, blood-pressure biology, and stromal remodeling. This workflow-focused guide shows how to control compound handling, separate receptor-specific effects from toxicity, and extend vascular assays toward the collagen-rich tumor microenvironment described in recent research.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-09-08

  Gu et al. show that palbociclib can suppress pancreatic ductal adenocarcinoma cell growth while paradoxically increasing migration, invasion, and epithelial-to-mesenchymal transition. Combining CDK4/6 inhibition with the BET inhibitor JQ1 enhanced antitumor activity and countered this invasive phenotype through coordinated regulation of GSK3β-mediated Wnt/β-catenin and TGF-β/Smad signaling.

8189 records 1/546 page Next 12345 下5页 Last page